X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Elranatamab Causes Recurrent Multi-Myeloma Clinical Response

Content Team by Content Team
28th December 2022
in Clinical Trials, News

Data shown at the 64th American Society of Haematology (ASH) conference in New Orleans demonstrates that elranatamab is effective and has a controllable effectiveness and safety in patients with relapsed or refractory multiple myeloma (RRMM).

Multiple myeloma (MM) is a clonal plasma cell proliferative condition that, if left unchecked, can eventually result in particular end-organ damage. It is characterised by an aberrant increase in monoclonal immunoglobulins. It is a rare form of cancer, with an age-standardized incidence rate of 178 cases per 100,000 people worldwide but a mortality rate of 114 cases per 100,000 people in the year 2020. Symptoms of organ involvement, such as hypercalcemia, renal insufficiency, anaemia, and bone abnormalities, are typically present in most patients. However, a small percentage of people are asymptomatic and are only discovered by abnormal blood or urine testing.

Elranatamab, a bispecific antibody that targets the expression of BCMA and CD3 on T cells and activates and reroutes the T-cell-driven immune response against MM, was the subject of data presentations at the ASH conference. The results came from the MagnetisMM-1 trial, which was created to evaluate elranatamab’s tolerability and safety in patients with relapsed or refractory multiple myeloma at ascending dose levels in order to establish the maximum tolerated dose and choose the suggested Phase 2 dose. Elranatamab was used in the trial and was given subcutaneously at doses ranging from 80 to 1000 g/kg either weekly or every two weeks.

The clinical reaction of elranatamab

Elranatamab was administered to 55 individuals with a median age of 64 years and a 27% black, African American, or Asian makeup. The median number of prior regimens was 5, with a range of 1 to 14, and 91% of the patients were triple-class refractory. Additionally, 69% of the patients had undergone prior stem cell transplantation, 29% had a high cytogenetic risk, and 24% had previously received BCMA-targeted therapy.

The objective response rate (ORR) was 64% after a median follow-up of 12.0 months, only including those with IMWC (International Myeloma Working Group) confirmed responses, with 56% of individuals achieving a very good partial response or better and 38% achieving a full response or better.

The Kaplan-Meier estimate for the median response time was 17.1 months among 35 respondents, and the chance of remaining event-free at 12 months was 59%.  Elranatamab produced long-lasting clinical and molecular effects, and at a sensitivity of 110-5, 100% (12/12) of evaluable patients had confirmed CR or best-achieved minimal residual disease (MRD) negativity, including 2 participants who continued to exhibit a stringent full response for more than two years.

The cytokine release syndrome was the most frequent treatment-emergent adverse effect, but it only occurred in 67% of patients and was only of grade 1 (33% of patients) or grade 2 intensity, with no grade 3 or higher reactions.

With an ORR of 64%, 38% of these patients achieved CR or better, and 100% of evaluable patients were able to attain MRD negative, the authors came to the conclusion that elranatamab produced long-lasting clinical and molecular responses in patients with relapsed or refractory MM. They continued by saying that these findings are in favour of elranatamab’s continued development for MM sufferers.

Previous Post

PAXLOVID, The First Oral COVID-19 Generic, Is WHO-Approved

Next Post

Developing Drugs That Target Multidrug-Resistant Bacteria

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
Developing Drugs That Target Multidrug-Resistant Bacteria

Developing Drugs That Target Multidrug-Resistant Bacteria

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In